Prognostic and Predictive Biomarkers in Gastroenteropancreatic Neuroendocrine Tumors
Abstract
Neuroendocrine tumors (NET) are a diverse group of tumors that derive from epithelial cells with neuroendocrine differentiation. Gastroenteropancreatic NETs are a subset of NET that arise from the gastrointestinal tract. The natural history and prognosis varies widely between different gastroenteropancreatic NETs, highlighting the importance of identifying accurate prognostic and predictive biomarkers. At the 2013 ASCO Gastrointestinal Cancers Symposium, De Braud et al. (Abstract #186) and Bellister et al. (Abstract #163) present data on two new possible biomarkers.
Image: Logo (Tufts Medical Center. Boston, MA, USA).
Downloads
References
Yao, James C et al. "One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States." Journal of Clinical Oncology 26.18 (2008): 3063-3072. PMID: 18565894
Ter-Minassian, Monica et al. "Prospective analysis of clinical outcomes and prognostic factors in patients with neuroendocrine tumors (NETs)." J Clin Oncol (Meeting Abstracts) May. 2010: 4044.
Arnold, Rudolf et al. "Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors." Clinical Gastroenterology and Hepatology 6.7 (2008): 820-827. PMID: 18547872
Oberg, K. “Gastrointestinal Neuroendocrine Tumors.” Annals of Oncology Supplement 7.(2010):vii72-80.
Yao, JC et al. "Everolimus for advanced pancreatic neuroendocrine tumors.” N Engl J Med. 2011 10;364(6):514-23. PMID: 21306238.
Raymond, Eric et al. "Sunitinib malate for the treatment of pancreatic neuroendocrine tumors." New England Journal of Medicine 364.6 (2011): 501-513. PMID: 21306237
Pavel, Marianne E et al. "Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study." The Lancet 378.9808 (2011): 2005-2012. PMID 22119496
Yao JC et al. “Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET).” J Clin Oncol 30, 2012 (suppl; abstr 4014).
De Braud et al. “Loss of succinate dehydrogenase (SDHB) in midgut carcinoids as a prognostic factor: A new marker of personalized cancer medicine in neuroendocrine tumors?” J Clin Oncol 30: 2012 (suppl 34; abstr 186)
Barletta, Justine A, and Jason L Hornick. "Succinate Dehydrogenase-deficient Tumors: Diagnostic Advances and Clinical Implications." Advances in Anatomic Pathology 19.4 (2012): 193-203. PMID 22692282
Bellister et al. “Prediction of prognosis in patients treated with everolimus for extrapancreatic neuroendocrine tumors by a single nucleotide polymorphism in PHLPP2.” J Clin Oncol 30: 2012 (suppl 34; abstr 163)
Bardella, Chiara, Patrick J Pollard, and Ian Tomlinson. "SDH mutations in cancer." Biochimica et Biophysica Acta (BBA)-Bioenergetics 1807.11 (2011): 1432-1443. PMID 21771581
O’Neill AK, Newton AC. PHLPP2 (PH domain leucine-rich repeat protein phosphatase 2). Atlas Genet Cytogenet Oncol Haemotol. June 2009.
Copyright (c) 2014 Ryan Stevenson, Steven k Libutti, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.